Drug Trial Radar · NCT06587451
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
52
Actual
Start
Dec 19, 2024
Primary completion
Jan 23, 2026
Study completion Jan 23, 2026
Sponsor
- Lead sponsor
- SandozNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate similar PK and efficacy and to show comparable safety and immunogenicity between JPB898, Opdivo-EU, and Opdivo-US, all administered in combination with Yervoy-EU (induction phase only), in participants with advanced (unresectable Stage III or metastatic Stage IV) melanoma.
Conditions
- Melanoma
Interventions
JPB898 (Induction and Maintenance)Drug
Induction and Maintenance: Intravenous (IV)
Opdivo-EU (Induction)Drug
Induction: Intravenous (IV)
Opdivo-US (Induction)Drug
Induction: Intravenous (IV)
Yervoy-EU (Induction)Drug
Induction: Intravenous (IV)
Opdivo-EU (Maintenance)Drug
Maintenance: Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate PK similarity between JPB898, Opdivo-US, and Opdivo-EUTime frame: Days 1 to 22
- Demonstrate PK similarity between JPB898, Opdivo-US, and Opdivo-EU between JPB898 and Opdivo-US/-EUTime frame: Days 64 to 85
- Demonstrate efficacy similarity for Best overall response (BOR) between JPB898 and Opdivo-US/-EU defined as the best overall response based on blinded central tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaTime frame: BOR (Complete response (CR) or partial response (PR)) from baseline up to 28 weeks
Locations
22 sites in 11 countries. Site status is shown where the registry gives one.
Sandoz Investigational Site 1
Santiago, Chile
Sandoz Investigational Site
Santiago, Chile
Sandoz Investigational Site 2
Tbilisi, Georgia
Sandoz Investigational Site
Athens, Greece
Sandoz Investigational Site
Thessaloniki, Greece
Sandoz Investigational Site
Pisa, Italy
Sandoz Investigational Site
Vilnius, Lithuania
Sandoz Investigational Site
Kuala Lumpur, Malaysia
Sandoz Investigational Site
Pulau Pinang, Malaysia
Sandoz Investigational Site
Putrajaya, Malaysia
Sandoz Investigational Site
Bacolod, Philippines
Sandoz Investigational Site
Warsaw, Poland
Sandoz Investigational Site
Lisbon, Portugal
Sandoz Investigational Site 1
Busan, South Korea
Sandoz Investigational Site
Daejeon, South Korea
Sandoz Investigational Site 2
Seoul, South Korea
Sandoz Investigational Site 2
Madrid, Spain
Sandoz Investigational Site
Málaga, Spain
Sandoz Investigational Site
Oviedo, Spain
Sandoz Investigational Site
Santander, Spain
Sandoz Investigational Site
Santiago de Compostela, Spain
Sandoz Investigational Site 2
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.